JP2022513072A5 - - Google Patents
Info
- Publication number
- JP2022513072A5 JP2022513072A5 JP2021527070A JP2021527070A JP2022513072A5 JP 2022513072 A5 JP2022513072 A5 JP 2022513072A5 JP 2021527070 A JP2021527070 A JP 2021527070A JP 2021527070 A JP2021527070 A JP 2021527070A JP 2022513072 A5 JP2022513072 A5 JP 2022513072A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- less
- composition according
- subject
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024232965A JP2025066731A (ja) | 2018-11-19 | 2024-12-27 | 腫瘍の処置におけるサバイビン治療薬の効能を改善するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769347P | 2018-11-19 | 2018-11-19 | |
| US62/769,347 | 2018-11-19 | ||
| PCT/IB2019/059899 WO2020104923A1 (en) | 2018-11-19 | 2019-11-18 | Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024232965A Division JP2025066731A (ja) | 2018-11-19 | 2024-12-27 | 腫瘍の処置におけるサバイビン治療薬の効能を改善するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513072A JP2022513072A (ja) | 2022-02-07 |
| JP2022513072A5 true JP2022513072A5 (https=) | 2022-11-28 |
Family
ID=70773553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527070A Pending JP2022513072A (ja) | 2018-11-19 | 2019-11-18 | 腫瘍の処置におけるサバイビン治療薬の効能を改善するための方法 |
| JP2024232965A Pending JP2025066731A (ja) | 2018-11-19 | 2024-12-27 | 腫瘍の処置におけるサバイビン治療薬の効能を改善するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024232965A Pending JP2025066731A (ja) | 2018-11-19 | 2024-12-27 | 腫瘍の処置におけるサバイビン治療薬の効能を改善するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220125903A1 (https=) |
| EP (1) | EP3883604A4 (https=) |
| JP (2) | JP2022513072A (https=) |
| CN (1) | CN113660949A (https=) |
| AU (1) | AU2019383785A1 (https=) |
| CA (1) | CA3119910A1 (https=) |
| TW (1) | TW202039532A (https=) |
| WO (1) | WO2020104923A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7642530B2 (ja) | 2018-09-04 | 2025-03-10 | トレオス バイオ リミテッド | ペプチドワクチン |
| CN118962103B (zh) * | 2022-03-15 | 2025-07-22 | 上海君赛生物科技有限公司 | 肿瘤特异性免疫细胞标志物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| ES2523172T3 (es) * | 2005-02-04 | 2014-11-21 | Survac Aps | Vacuna de péptido de survivina |
| CA2908042C (en) * | 2013-03-27 | 2023-01-31 | Immunovaccine Technologies Inc. | Method for improving the efficacy of a survivin vaccine in the treatment of cancer |
| CN105873941A (zh) * | 2013-12-16 | 2016-08-17 | 默克专利有限公司 | 生存素导向的癌症疫苗治疗 |
| JP6851983B2 (ja) * | 2015-05-01 | 2021-03-31 | イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法 |
| EP3291842A4 (en) * | 2015-05-07 | 2019-01-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | SURVIVIN VACCINE VARIANT FOR THE TREATMENT OF CANCER |
-
2019
- 2019-11-18 US US17/294,713 patent/US20220125903A1/en not_active Abandoned
- 2019-11-18 JP JP2021527070A patent/JP2022513072A/ja active Pending
- 2019-11-18 CN CN201980089403.9A patent/CN113660949A/zh active Pending
- 2019-11-18 CA CA3119910A patent/CA3119910A1/en active Pending
- 2019-11-18 AU AU2019383785A patent/AU2019383785A1/en not_active Abandoned
- 2019-11-18 EP EP19887650.0A patent/EP3883604A4/en not_active Withdrawn
- 2019-11-18 WO PCT/IB2019/059899 patent/WO2020104923A1/en not_active Ceased
- 2019-11-19 TW TW108141982A patent/TW202039532A/zh unknown
-
2024
- 2024-12-27 JP JP2024232965A patent/JP2025066731A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hovhannisyan et al. | CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks | |
| ES2727154T3 (es) | Combinación | |
| JP2017523187A5 (https=) | ||
| JP2019527696A5 (https=) | ||
| KR20220007593A (ko) | 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 | |
| CN104853776A (zh) | 免疫应答的增强 | |
| JP2024069198A (ja) | 活性剤及び免疫調節剤のリンパ節への標的化送達のための方法及び組成物 | |
| KR20120083359A (ko) | ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법 | |
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2019526528A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| WO2017035453A1 (en) | Compositions and methods for treating solid tumors | |
| JP2025515092A5 (https=) | ||
| KR20210035805A (ko) | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| JP2022513072A5 (https=) | ||
| Skarbnik et al. | Safety and efficacy of consolidation therapy with ipilimumab plus nivolumab after autologous stem cell transplantation | |
| BR112020022294A2 (pt) | composição e uso de uma composição | |
| US20240374644A1 (en) | Herv-k antibody therapeutics | |
| US20230114276A1 (en) | Modulating anti-tumor immunity | |
| JP2021505659A (ja) | 癌治療のためのｔｒｐｖ６阻害剤および併用療法 | |
| EP4319815A1 (en) | Dosing of bispecific t cell engager | |
| US20210260008A1 (en) | Combination therapy for treating cancer | |
| WO2021009761A1 (en) | Combination therapy for the treatment of cancer | |
| Arabpour et al. | Cancer immunotherapy |